Corrected dates regarding last day of trading in BTA
In press release published today, December 9, 2016, dates regarding trading in BTA was stated. Corrected dates regarding last day of trading in BTAs (paid subscription share) is December 16th, 2016 and stop day is December 19th, 2016.
774,984 shares are registered at the Swedish Companies Registration Office and is estimated to be distributed to each VP account/depot on December 21, 2016. After the new rights issue registration, the total number of shares in Oncology Venture are 10 074 794 shares. The share capital after the registration is SEK 1 410 471,16.
Financial Advisor
Sedermera Fondkommission has acted as Oncology Ventures financial advisor in relation to the new rights issue.
For questions related to the new issue, please contact:
Sedermera Fondkommission
Telefon: + 46 40 - 615 14 10
E-post: info@sedermera.se
For further information about Oncology Venture, please contact:
| Ulla Hald Buhl, COO andChief IR & CommunicationsMobile: +45 2170 1049uhb@oncologyventure.com | Or | Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: pbj@oncologyventure.com |
This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 9th 2016.
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.